Free Trial

BioCardia Q1 2024 Earnings Report

BioCardia logo
$2.26 +0.08 (+3.67%)
(As of 05:34 PM ET)

BioCardia EPS Results

Actual EPS
-$1.35
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
-$2.55

BioCardia Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioCardia Announcement Details

Quarter
Q1 2024
Time
After Market Closes
Grab This Altcoin Before Trump's Crypto Announcement (Ad)

Under-the-Radar Crypto Could Soar by Jan. 20th Investors in the know could bank HUGE profits!

Click HERE to access this free report

BioCardia Earnings Headlines

⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
BioCardia Reports Q3 2024 Progress and Financials
BioCardia’s Strong Q3 Performance and Strategic Trials Drive Buy Rating
See More BioCardia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioCardia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCardia and other key companies, straight to your email.

About BioCardia

BioCardia (NASDAQ:BCDA), a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

View BioCardia Profile

More Earnings Resources from MarketBeat